title: Is performing lobectomy after the use of bevacizumab for a lung tumor dangerous?
abstract: Recent new drugs, such as bevacizumab (Bev), also result in a remarkable response. However, the safety of major lung resection after the use of Bev remains controversial. Is it really dangerous to perform major lung resection after the use of Bev for a lung tumor? In this report, we describe two patients who underwent surgery safely without fragile pathological findings of the vessels.
authors.affiliation: Department of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, Saitama 362-0806, Japan.
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.affiliation: Department of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, Saitama 362-0806, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakajima
authors.affiliation: Department of Thoracic Surgery, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, Saitama 362-0806, Japan.
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Kinoshita
keywords: Bev, bevacizumab; Bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; CT, computed tomography; DTX, docetaxel; FDG, fluorodeoxyglucose; LA-NSCLC NSCLC, locally advanced non-small cell carcinoma; Lung cancer; PET, positron emission tomography; PTX, paclitaxel; Surgery; VEGF, vascular endothelial growth factor